Molecular biology: Micro-conspirator

    Article metrics

    Cell 135, 437–448 (2008) 10.1016/j.cell.2008.08.041

    An existing cancer drug may be effective against a specific type of nerve tumour because of its ability to block a particular metabolic pathway.

    Wade Clapp at the Indiana University School of Medicine in Indianapolis, Luis Parada at the University of Texas Southwestern Medical Center in Dallas and their colleagues studied mice with tumours that derived their cancerous nature from a mutation in a gene called Nf1. For the tumours to grow, a biochemical pathway, c-kit, must be activated in bone-marrow cells with only one healthy copy of the gene, and immune cells called 'mast' cells from the bone marrow must have migrated close to the tumour cells.

    The authors suppressed the tumours' growth with the c-kit-inhibiting drug imatinib mesylate (Gleevec). Imatinib was then given to a child with a life-threatening NF1-dependent tumour, which subsequently shrank by about 70%.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Molecular biology: Micro-conspirator. Nature 456, 144–145 (2008) doi:10.1038/456144e

    Download citation

    Comments

    By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.